Qiagen (NYSE:QGEN) Now Covered by Analysts at Barclays

by · The Cerbat Gem

Barclays started coverage on shares of Qiagen (NYSE:QGEN – Free Report) in a research report released on Tuesday, MarketBeat reports. The brokerage issued an overweight rating and a $55.00 price objective on the stock.

QGEN has been the topic of several other reports. Wall Street Zen upgraded shares of Qiagen from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 15th. Robert W. Baird boosted their price objective on shares of Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a research report on Monday, April 21st. Finally, Redburn Atlantic cut Qiagen from a “buy” rating to a “neutral” rating in a report on Friday, April 4th. Seven analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $49.30.

Check Out Our Latest Stock Analysis on QGEN

Qiagen Trading Up 1.3%

QGEN opened at $48.07 on Tuesday. The firm’s fifty day moving average is $44.06 and its two-hundred day moving average is $42.51. The firm has a market cap of $10.68 billion, a PE ratio of 120.51, a price-to-earnings-growth ratio of 2.42 and a beta of 0.67. Qiagen has a twelve month low of $37.63 and a twelve month high of $49.30. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.83 and a current ratio of 3.37.

Qiagen (NYSE:QGEN – Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.05. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. The firm had revenue of $483.46 million during the quarter, compared to analysts’ expectations of $465.66 million. During the same period in the previous year, the firm earned $0.44 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis. Equities research analysts anticipate that Qiagen will post 2.26 EPS for the current year.

Institutional Trading of Qiagen

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sanctuary Advisors LLC raised its stake in shares of Qiagen by 2.8% during the 4th quarter. Sanctuary Advisors LLC now owns 20,049 shares of the company’s stock worth $892,000 after purchasing an additional 543 shares in the last quarter. Private Advisor Group LLC increased its holdings in Qiagen by 24.2% during the fourth quarter. Private Advisor Group LLC now owns 7,766 shares of the company’s stock worth $346,000 after buying an additional 1,515 shares during the last quarter. Ieq Capital LLC acquired a new stake in Qiagen in the fourth quarter valued at $432,000. Illinois Municipal Retirement Fund lifted its stake in Qiagen by 46.4% in the fourth quarter. Illinois Municipal Retirement Fund now owns 64,318 shares of the company’s stock valued at $2,864,000 after acquiring an additional 20,375 shares during the last quarter. Finally, Proficio Capital Partners LLC bought a new position in shares of Qiagen in the 4th quarter valued at about $1,521,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

(Get Free Report)

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Further Reading